Page 6 - Oncological Sciences News Today

Scientists from Mount Sinai have recently found potentially serious side effects related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma.

New York, NY (PRWEB) November 30, 2021 -- The National Cancer Institute has awarded Mount Sinai researchers $3.15 million in grant funding to assess the

New York, NY (PRWEB) October 19, 2021 -- Patients with the blood cancer multiple myeloma often mount a poor antibody response to COVID-19 vaccines. Mount

The findings of a new study by Mount Sinai and UC San Diego researchers, for the first time, have shown how mutations affecting a cellular process called RNA sp

Mount Sinai and UC San Diego researchers have shown for the first time how mutations affecting a cellular process called RNA splicing alter cells to develop myelodysplastic syndrome (MDS) and other hematologic malignancies and solid tumors, according to a study published in Cancer Discovery in October.

Mount Sinai researchers have developed a therapy that shows promise against a deadly pediatric leukemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September.

The absence of a protein that activates the body's antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition that is treatable with an FDA-approved class of drugs known as TNF (tumor necrosis factor) inhibitors, a global research team led by Mount Sinai has found.

The absence of a protein that activates the body’s antiviral defenses can cause a rare rheumatoid-like autoinflammatory condition called TBK1, which is treatable with an existing FDA-approved drug.

Novel therapeutic agent could be effective for treating cancers with certain gene mutations Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery, a journal of the American Association for Cancer Research, in July. The therapy is an engineered molecule, named MS21, that causes the degradation of AKT, an enzyme that is overly active in many...